Can Real-Time MRI make radiation safer for Ultra-Central lung tumors?
NCT ID NCT07733219
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether MRI-guided stereotactic body radiotherapy (SBRT) can safely treat ultra-central lung tumors—growths located near the windpipe and major airways. Using an MR-LINAC machine, doctors can adjust the radiation beam in real time as the patient breathes, potentially sparing healthy tissue. The study enrolls adults with early-stage lung cancer or isolated tumor recurrences in the chest, and tracks whether this technique lowers the chance of severe side effects like lung scarring or bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MRI-guided stereotactic body radiotherapy (SBRT) delivered via MR-LINAC
- What this could lead to
- If successful, this approach could offer a safer way to treat hard-to-reach lung tumors with high-dose radiation, reducing the risk of severe side effects.
- What could go wrong
- This is an early-phase trial with only 59 participants, so results may not apply broadly. The treatment still carries risks of serious lung or airway damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (T1 N0 M0 AND T2 N0 M0) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.